Abstract
Introduction. Malignant neoplasms of the upper gastrointestinal tract occupy the 6th position in terms of the frequency of detection of new cases of cancer. Within the framework of the Federal project “Fight against oncological diseases”, state tasks have been set that provide for a significant reduction in mortality from neoplasms, including malignant ones, to 185 cases per 100,000 people. The development, standardization and algorithmization of medical methodologies for drug treatment of cancer aimed at improving the quality of oncological care is underway. In early June 2022, the results of the latest clinical developments, including targeted and immune therapy for upper gastrointestinal tumors, were presented at the Annual Congress of the American Society of Clinical Oncology (ASCO). Popularization of innovative approaches to the treatment of cancerous tumors of the gastrointestinal tract fully meets the objectives of the Federal project.
Materials and methods. This material was the result of a study of innovative clinical developments in drug therapy for tumors of the upper gastrointestinal tract, presented at the ASCO Annual Congress - June 2022 and the digital platform MEDTalks.nl: the Korean clinical trial K-Umbrella; the German-Swiss Phase 2b DANTE clinical trial; French national randomized trial GERCOR.
Discussion and Conclusions. The results of the presented clinical developments demonstrate positive effects and an acceptable drug safety profile, which opens up prospects for their implementation in practice as part of innovative medical methodologies for the treatment of patients with malignant neoplasms of the upper gastrointestinal tract.
For citation: Andreev D. A., Zavyalov A. A., Modern scientific and clinical developments in the treatment of malignant neoplasms of the upper gastrointestinal tract: results of ASCO-2022. City Healthсare. 2022;3(3):77–84 doi:10.47619/2713-2617.zm.2022.v.3i3;77–84
Полный текст
Список литературы
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin [Internet]. 2021 May 4;71(3):209–49. Available from: https://onlinelibrary.wiley.com/doi/10.3322/caac.21660
2. Stilidy IS, Gevorkyan TG, Shpak AG. Improvement of indicators of the federal project "Fight against oncological diseases". Bulletin of Roszdravnadzor. 2021;1 P. 46–53.
3. Tryakin AA, Fedyanin MY, Pokataev IA, Petrovsky AV. Pending issues of standard approaches in oncology. Pract Oncol [Internet]. 2020 Jun 30;2(2020):81–90. Available from: https://www.practical-oncology.ru/articles/81-90.pdf
4. American Society of Clinical Oncology. ASCO Annual Meeting 2022 [Internet]. 2022 [cited 2022 Jun 14]. Available from: https://meetings.asco.org/meetings/2022-asco-annual-meeting/288/program-guide/scheduled-sessions
5. MEDtalks, Laarhoven H van. Highlights Upper GI-tumoren. ASCO 2022 highlights voor wat betreft de Upper GI-tumoren. [Internet]. 2022 [cited 2022 Aug 19]. Available from: https://www.medtalks.nl/asco2022-hannekevanlaarhoven
6. Rha SY, Lee C, Kim HS, Jung M, Kim H, Woo Kyun B, et al. The first report of K-Umbrella Gastric Cancer Study: An open label, multi-center, randomized, biomarker-integrated trial for second-line treatment of advanced gastric cancer (AGC). J Clin Oncol [Internet]. 2022;40(16\_suppl):4001. Available from: https://doi.org/10.1200/JCO.2022.40.16_suppl.4001
7. Al-Batran S-E, Lorenzen S, Thuss-Patience PC, Homann N, Schenk M, Lindig U, et al. Surgical and pathological outcome, and pathological regression, in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy versus FLOT alone for resectable esophagogastric adenocarcinoma: Interim results from DANTE, a randomize. J Clin Oncol [Internet]. 2022;40(16\_suppl):4003. Available from: https://doi.org/10.1200/JCO.2022.40.16_suppl.4003
8. Neuzillet C, Bouché O, Tournigand C, Chibaudel B, Bouguion L, Bengrine-Lefevre L, et al. Adapted physical activity in patients (Pts) with advanced pancreatic cancer (APACaP): Results from a prospective national randomized GERCOR trial. J Clin Oncol [Internet]. 2022;40(16\_suppl):4007. Available from: https://doi.org/10.1200/JCO.2022.40.16_suppl.4007
9. National Library of Medicine. Biomarker-Integrated Umbrella, Advanced Gastric Cancer. [Internet]. 2022 [cited 2022 Aug 18]. Available from: https://clinicaltrials.gov/ct2/show/NCT02951091
10. Korea Biomedical Review, Yun-mi K, Rha SY. [ASCO 2022] K-Umbrella gastric cancer trial shows Korea’s cancer study capabilities. [Internet]. 2022 [cited 2022 Aug 19]. Available from: http://www.koreabiomed.com/news/articleView.html?idxno=13883
11. National Library of Medicine. Evaluation of an Adapted Physical Activity Program in Patients With Unresectable Pancreatic Cancer. [Internet]. 2022 [cited 2022 Aug 18]. Available from: https://clinicaltrials.gov/ct2/show/NCT02184663
12. Russian Society of Clinical Oncology (RUSSCO), Tryakin AA. ASCO News 2022. Esophageal and Gastric Cancer. [Internet]. 2022 [cited 2022 Aug 19]. Available from: https://www.rosoncoweb.ru/news/oncology/2022/07/13/
13. Högner A, Moehler M. Immunotherapy in Gastric Cancer. Curr Oncol [Internet]. 2022 Mar 2;29(3):1559–74. Available from: https://www.mdpi.com/1718-7729/29/3/131
14. Hoshino I, Yokota H. Radiogenomics of gastroenterological cancer: The dawn of personalized medicine with artificial intelligence-based image analysis. Ann Gastroenterol Surg. 2021 Jul;5(4):427–35.
15. Ognerubov N.A., Shatov I.A., Shatov A.V. Radiogenomics and radiomics in the diagnosis of malignant tumors: a review of the literature // Bulletin of the Tambov University. Series Natural and technical sciences. Tambov, 2017. Vol. 22. Issue. 6. P. 1453-1460. DOI: 10.20310/1810-0198-2017-22-6-1453-1460
16. Andreev D.A., Zavyalov A.A. Approaches in the organization of oncological care. In the collection Proceedings of the Research Institute of Health Organization and Medical Management Collection of scientific papers Under the general editorship of EI Aksenova. 2021, P. 89–94.
Файлы
Статистика
Просмотры аннотации: 423
Просмотры XML: 0
Просмотры PDF: 349
Всего: 772